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Summary To clarify the meaning and clinical value of bone formation markers in bone metastasis from prostate cancer, we investigated
the bone formation markers carboxy-terminal propeptide of type procollagen (PICP), bone-specific alkaline phosphatase (BAl-p) and
osteocalcin, so-called bone gla protein (BGP) in 43 prostate cancer patients with and 46 patients without overt bone metastasis. Patients with
bone metastasis were evaluated repeatedly by bone scan at intervals of 3-6 months. The expression patterns of bone formation markers in
patients with progression of bone metastasis became dissociated; BAl-p and PICP were elevated in patients with progression of bone
metastasis but BGP was not. Instead, BGP showed slight elevation in patients with improvement and complete remission of bone metastasis.
PICP, BAl-p and BGP are all bone formation markers, but each marker appears in a different phase of bone formation: PICP appears in
proliferation phase, BAl-p appears in matrix maturation phase and BGP appears in late bone formation phase. Ourfindings that BGP was not
elevated in progression of bone metastasis and that it increased slightly with improvement and complete remission of bone metastasis may
imply that the bone formation that occurs in blastic bone metastasis is different from normal bone formation.
Keywords: prostate cancer; bone metastasis; carboxy-terminal propeptide of type procollagen; bone-specific alkaline phosphatase; bone
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Bone metastasis from prostate cancer is frequently osteoblastic
in nature, and it often shows up as osteoplastic changes on plain
radiography. Recently, various bone metabolic markers of both
formation and resorption have been identified. Bone resorption
markers have been proven to be useful in the bone metastasis of
prostate cancer (Kylmala et al, 1995; Maeda et al, 1996).
However, the meaning of bone formation markers is not fully
understood in bone metastasis of prostate cancer. Various bone
formation markers have been found to be associated with certain
phases of bone formation. The carboxy-terminal propeptide of
type I procollagen (PICP) is believed to be a marker ofearly bone
formation and it generally appears during osteoblast proliferation.
Bone-specific alkaline phosphatase (BAl-p) is a marker of the
middle stage ofbone formation and it appears in the matrix matu-
ration phase. Osteocalcin, so-called bone gla protein (BGP), is a
marker oflate bone formation and it appears in the mineralization
phase (Stein et al, 1990; Risteli and Risteli, 1993; Zhou et al, 1994;
Calvo et al, 1996). To clarify the meaning of bone formation
markers, we investigated these three markers in prostate cancer
patients with and without overt bone metastasis.
PATIENTS AND METHODS
Between October 1994 and April 1996, 43 prostate cancer patients
with and 46 patients without overt bone metastasis were studied
with respect to bone formation markers. Ofthe 46 patients without
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overt bone metastasis, 29 had a history of radical prostectomy or
radiotherapy and the other 17 were newly diagnosed patients and
underwent radical prostectomy orradiotherapy afterbone scan and
serum sampling. The median age of the patients without overt
bone metastasis was 69 years (range 47-85 years) and the clinical
stage of these patients was stage A in four patients, B in 14, C in
19 and DI in nine. Of the 43 patients with bone metastasis, nine
were newly diagnosed and were receiving hormone manipulation
after bone scan and serum sampling. The other 34 patients were
under active treatment with hormonal manipulation and/or
chemotherapy at various intervals from initiation of these thera-
pies, and the patients were at various stages of response. The
median age of the patients with bone metastasis was 69 years
(range 53-83 years).
All patients were evaluated by bone scan at the time of serum
sampling. Some ofthe patients with bone metastasis were studied
repeatedly. At each sampling time, the patients with bone metas-
tasis were evaluated based on the finding of bone scan compared
with the previous bone scan with information ofsymptom change,
PSA value and/or other imaging modalities; new (NEW),
complete remission (CR), improvement (IMP), flare-up (FLARE),
no change (NC) and progression of disease (PROG) based on
national prostatic cancer project response criteria (Slack and
Murphy, 1984; Francini et al, 1993). NEW indicates newly diag-
nosed bone metastasis. FLARE was defined when a patient
showed progression of bone metastasis on bone scan within
6 months of the start of hormone therapy with improvement of
symptom and PSA level and then showed improvement on bone
scan finding at later studies (Pollen et al, 1984).
After informed consent was obtained, the sera samples were
drawn at the time of bone scan and kept frozen at -40°C until
analysis. Bone formation markers, PICP, BAl-p and BGP were
analysed. A bone resorption marker, pyridinoline cross-linked
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carboxy-terminal telopeptide (ICTP), was also measured. PICP
was measured by a radioimmunoassay (PICP RIA kit, Orion
Diagnostica, Epsoo, Finland). BAl-p was measured by an enzyme
immunoassay (Alkpase-B kit, Metra Biosystems, CA, USA).
BGP was measured by an immunoradiometric assay using tracer
anti-BGP (12-33) antibody and solid phase anti-BGP (30-49) anti-
body with synthetic human BGP (1-49) as a standard (Mitsubishi
BGP-IRMA kit, Mitsubishi Chemical, Tokyo, Japan). ICTP was
measured by a radioimmunoassay (Orion Diagnostica, Espoo,
Finland). The reference values ofeach marker were 170 ng ml-' for
PICP, 30 U 1-' for BAl-p, 9.9 ng ml-' for BGP and 4.9 ng ml-' for
ICTP (Koizumi et al, 1995; Maeda et al, 1996). The sensitivity and
specificity were calculated based on these reference values.
The data are expressed as the mean ± s.d. The Z-score in
patients with bone metastasis was calculated using the mean
and the s.d. of patients without bone metastasis. The Z-score =
(value - the mean of patients without bone metastasis)/s.d. of
patients without bone metastasis. The statistical analysis was per-
formed by one-way ANOVA followed by Fisher's PLSD method.
A P-value ofless than 0.05 was considered to be significant.
RESULTS
As shown in Table 1, BAl-p was markedly elevated in patients
with bone metastasis and PICP was also elevated. However, BGP
elevation was not significant in patients with bone metastasis than
in those without bone metastasis. From the mean and s.d. ofthese
markers in patients without bone metastasis, the Z-score of each
marker was calculated.
The sampling time with bone metastasis was as follows: nine
NEW, 15 CR, 15 IMP, three FLARE, 15 NC and 39 PROG. Figure
1 summarizes the Z-score and s.e.m. of each marker in various
states of bone metastasis. PICP showed significant elevation in
PROG (Z-score = 3.87). Although not significant, mild elevation
ofPICP was noted in CR (Z-score = 1.97), NC (Z-score = 1.34) and
IMP (Z-score = 1.26). No elevation of PICP was shown in NEW
(Z-score = 0.11) and FLARE (Z-score = 0.08). BAl-p showed
significant elevation in PROG (Z-score = 24.50). BAl-p showed
moderate elevation in NC (Z-score = 8.23). BAl-p elevation,
though not significant, was seen in FLARE (Z-score = 3.40), IMP
(Z-score = 2.39), CR (Z-score = 2.18) and NEW (Z-score = 1.82).
BGP showed no change in PROG (Z-score = 0.05), NEW
(Z-score = 0.08), NC (Z-score = 0.04) and FLARE (Z-score =
-0.18). BGP showed slight but significant elevation in CR (Z-score
= 1.30) and IMP (Z-score = 1.25). In FLARE, only BAI-p showed
elevation (not significant), PICP and BGP stayed at low levels.
Table 2 shows the sensitivity and specificity of each formation
marker. The results are similar to those ofthe Z-score analysis.
Table 1 Values of bone formation markers
Without bone metastasis With bone metastasis
Mean s.d. Mean s.d.
PICP (ng ml-') 105.8 32.03 179.4 260.65
BA1-p (U I-') 17.8 5.29 82.9 143.63
BGP (ng ml-') 4.57 3.12 5.86 6.15
A statistically significant difference is shown in PICP and BAl-p between
patients with and without bone metastasis.
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Figure 1 The data are expressed as mean ± s.e.m. The Z-score in patients
with bone metastasis was calculated using the mean and the s.d. of patients
without bone metastasis. Z-score = (value - the mean of patients without
bone metastasis)/s.d. of patients without bone metastasis. CR, complete
remission; FLARE, flare-up; IMP, improvement; NC, no change; NEW, new;
PROG, progression of disease; PICP, carboxy-terminal propeptide of type
procollagen; BAl -p, bone-specific alkaline phosphatase; and BGP,
osteocalcin, so-called bone gla protein. *P+ 0.05. **P± 0.05 compared with
the values in patients without bone metastasis
Figure 2 shows the balance of bone formation and resorption.
The difference in Z-scores ofBAl-p and ICTP is shown in various
conditions (Z-score of BAl-p minus Z-score of ICTP at each
point). In NEW, bone formation and resorption was balanced. In
PROG, bone formation greatly exceeded bone resorption. In NC,
FLARE, CR and IMP, bone formation and resorption were essen-
tially balanced even though bone formation was slightly greater
than bone resorption.
Table 2 Sensitivity and specificity of bone formation markers in bone
metastasis
Reference value n PICP BA1-p BGP
(170 ng ml-') (30 UI-1) (9.9 ng ml-')
Sensitivity (%)
Overall 96a 31.6 52.1 19.6
NEW 9 11.1 33.3 11.1
CR 15 35.7 33.3 26.7
IMP 15 28.6 46.7 45.3
FLARE 3 0 66.7 0
NC 15 31.2 60 6.7
PROG 39 38.5 61.5 15.4
Specificity (%) 46 93.3 97.8 93.5
Sensitivity = 100x no. of cases of above reference value with bone
metastasis/no. of cases with bone metastasis. Specificity = 100x no. of cases
within reference value without bone metastasis/no. of cases without bone
metastasis. aSeveral patients were studied repeatedly. The total number of
patients is 43. NEW, new; CR, complete remission; IMP, improvement;
FLARE, flare-up; NC, no change; PROG, progression.
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Figure 2 The data are expressed as mean ±s.em. The values are Z-score
of BAl-p minus Z-score of ICTP CR, complete remission; IMP, improvement;
FLARE, flare-up; NC, no change; NEW, newly diagnosed; PROG,
progression of disease; BA1-p, bone-specific alkaline phosphatase; ICTP,
pyridinoline cross-linked carboxy-terminal telopeptide. No statistically
significant difference is shown
DISCUSSION
Bone metastasis ofprostate cancer is characterized by an excess of
osteoblastic activity. Acceleration of bone formation in cases of
bone metastasis is no surprise. Various bone metabolic markers
have been measured in prostate cancer patients and have been
reported (Francini et al, 1988; Shin et al, 1990; Arai et al, 1992;
Sano et al, 1994; Koizumi et al, 1995).
The phenotypic developmental sequence ofosteoblasts has been
divided into three consecutive phases: proliferation, extracellular
matrix maturation and mineralization (Stein et al, 1990; Risteli and
Risteli, 1993; Zhou et al, 1994). In the early or proliferation phase
of osteoblast development, the type I collagen, transforming
growthfactor4P, and fibronectin genes are actively expressed, and
PICP is cleaved offprocollagen. Therefore, PICP is believed to be
a marker of the early or proliferation phase of osteoblast. In the
middle or matrix maturation phase, the expression of alkaline
phosphatase mRNA and its protein are increased followed by a
rapid decline when the osteoblast enters the mineralization phase.
Al-p and BAI-p are considered to be markers ofthe matrix matura-
tionphase. In the late phase ofosteoblast development, osteocalcin
(BGP) gene is expressed (Stein et al, 1990; Zhou et al, 1994).
Therefore, BGP is considered to be a marker of late bone forma-
tion even though the biological role ofBGP is not fully understood
(Stein et al, 1990; Risteli and Risteli, 1993; Zhou et al, 1994;
Calvo et al, 1996).
In the present study, we showed that PICP and BAI-p increased
significantly with the progression of bone metastasis. Although
BGP increased only slightly with the progression of bone metas-
tasis, the increase was significant in patients with improvement of
bone metastasis (IMP and CR). This may suggest that bone forma-
tion in the progression of bone metastasis is different from normal
bone formation. There is a possibility that BGP may be related to
the regulation of bone formation, i.e. BGP gene or protein may be
associated with stopping the excess bone formation. In an animal
study, Price et al (1982) reported that rats chronically treated by
warfarin showed excessive bone formation with growth plate and
they suggested the possibility ofrelationship between the decrease
of BGP and excessive bone folr ation; and recently Ducy et al
(1996) reported that osteocalcin gene knock-out mice showed an
increase ofbone formation without any change ofbone resorption
or mineralization, resulting in an increase of cortical bone thick-
ness and density - the BGP may be a negative regulator of bone
formation. In the progression ofbone metastasis, the lack of BGP
elevation may be associated with the increase of excess bone
formation. With improvement (IMP and CR) of bone metastasis,
the elevation of BGP may reduce the excess bone. It is also
suggested that the discrepancy in bone formation markers in bone
metastasis from prostate cancer may be caused by additional
factors, such as cytokines that are secreted from malignant
tumours. Further studies, including the search for other related
factors, are necessary to clarify the process that underlies bone
formation in cases ofbone metastasis from prostate cancer.
In practical terms, BAl-p seemed to be the most sensitive forma-
tion marker for evaluating bone metastasis from prostate cancer.
PICP was not as sensitive as BAl-p in the diagnosis and follow-up
of bone metastasis from prostate cancer, and BGP seemed to be
difficult to use for the diagnosis ofbone metastasis. However, the
elevation ofBGP may reflect the improvement ofbone metastasis.
Histologically, there is much less bone destruction than new
bone formation, and there are few osteoclasts but many active
osteoblasts surrounded by proliferated stromal cells in the bone
metastasis of patients with prostate cancer (Aoki et al, 1986).
However, both boneresorption and formation markers increased in
patients with bone metastasis from prostate cancer (Koizumi et al,
1995; Kylmala et al, 1995). We also investigated the balance of
bone formation and resorption by comparing the Z-scores ofBAl-p
and ICTP. The increase ofBAl-p exceeded that ofICTP. However,
bone resorption markers seemed to have better correlation with the
extent of the bone metastatic burden (Maeda et al, 1997) and a
resorption marker was reported to be ofprognostic value (Kylmala
et al, 1995). Both formation and resorption markers should be
measured in the follow-up ofbone metastasis from prostate cancer.
In conclusion, we showed that bone formation markers in bone
metastasis from prostatic cancerbecame dissociated. Although the
bone formation markers that appeared in early or proliferation
phase (PICP) and a marker of middle or matrix maturation phase
(BAl-p) were increased in the patients with progression of bone
metastasis, a bone marker that appeared in the late bone formation
phase (BGP) was not increased with the progression of bone
metastasis. BGP was, however, increased in the patients with
improvement and complete remission of bone metastasis. Thus,
bone formation associated with the progression ofbone metastasis
from prostate cancer may be different from normal bone formation.
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